INFECTIOUS DISEASE

Resistant Raoultella Ornithinolytica Bacteremia
in a Patient with New Acute Myeloid Leukemia
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INTRODUCTION
Members of the Raoultella genus were formerly considered
to be Klebsiella species until they were differentiated based
on phylogenetic Deoxyribonucleic acid (DNA) analysis.1
Since then, Raoultella ornithinolytica has been sparsely
implicated in clinically-apparent disease, though more
case reports are appearing as of late. Here we report the
first documented instance of R. ornithinolytica bacteremia
in a patient with new acute myeloid leukemia (AML).

CASE PRESENTATION
A 71-year-old man was transferred to our hospital for
treatment of newly discovered AML. Prior to transfer, he
experienced an aching abdominal pain attributed to
pancreatitis and daily episodes of watery diarrhea for
five days.
On admission, he had an oral temperature of 102.7°F,
pulse of 96 beats per minute, blood pressure of 145/70
mmHg, and oxygen saturation of 97% on room air.
Physical exam revealed gray-brown granular material
along the gum line of the third tooth that was tender to
palpation, tender lymphadenopathy in the right
submandibular space and right anterior cervical chain, a
grade 2/6 systolic murmur, and no peripheral edema.
Abdominal exam revealed tenderness and guarding over
the left upper quadrant and epigastrium. The remainder
of the physical exam was unremarkable.
Lab work revealed a white blood cell (WBC) count of 25.0
x 109/L with 52% blasts, hemoglobin of 7.4 g/dL, and
platelets of 36,000 x 109/L. Lipase, liver enzymes, and
creatinine were within normal limits. There was no
acid-base derangement. Nucleic acid amplification
testing for Clostridium difficile toxin was negative.
Since initial imaging was not available, a computed
tomography (CT) scan of the abdomen without contrast
was performed showing duodenitis—but not pancreatitis.
Further diagnostic workup was deferred to expedite the
initiation of chemotherapy for the patient’s concomitant
AML. Ten days of empiric therapy for Helicobacter pylori
was completed with clarithromycin 500 mg PO every 12
hours, amoxicillin 1 g PO every 12 hours, and pantoprazole
40 g PO daily.
Hydroxyurea was administered due to a steadily increasing
WBC count which peaked at 36.4 x 109/L. The patient
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remained febrile during this time and was considered
functionally neutropenic due to his malignancy, therefore
was treated for neutropenic fever with piperacillintazobactam 3.375 g IV every 6 hours.
On day 6 of his hospitalization, induction chemotherapy
was begun with a "7+3" regimen of idarubicin and
cytarabine. From approximately day 8 to day 35 of his
hospitalization, he remained neutropenic with an absolute
neutrophil counts (ANC) in the 0.2-0.3 x 109/L range and
his piperacillin-tazobactam was continued. His abdominal
pain and diarrhea persisted over this time.
On day 14, the patient's fever curves shifted from
100-101 °F to 101-103°F. On day 16, a CT scan of the
abdomen with contrast was again performed, showing
evidence of ongoing duodenitis without additional
pathology. Blood cultures were redrawn on days 15, 16,
and 17 and were all negative.
On day 19, FilmArray Blood Culture Identification Panel by
BioFireDx identified the family Enterobacteriaceae from
cultures taken that same day and while the patient was
still on piperacillin-tazobactam. The test was negative for
Enterobacteriaceae cloacae complex, Escherichia coli,
Klebsiella oxytoca, Klebsiella pneumoniae, Proteus, and
Serratia marcescens; this is the extent of the genera of
Enterobacteriaceae included in this particular test.
Overnight on day 20, the patient vomited and aspirated in
his sleep, developing acute hypoxia to SpO2 of 74% on
room air, respiratory rate of 34 breaths per minute, and
pulse of 133 beats per minute. A portable chest x-ray
showed a possible consolidation in the right lower lobe.
Due to the patient's extended hospital stay and immunocompromised status, vancomycin was added and
piperacillin-tazobactam was changed to meropenem.
On day 21, a lactose-fermenting gram-negative rod was
identified from the blood culture obtained two days prior.
Our lab reported that this most closely resembled
Raoultella ornithinolytica. Antibiotic susceptibility patterns
were remarkable for resistance to piperacillin-tazobactam
with MIC >64/4 mcg/mL. The organism was susceptible
to amikacin and meropenem (Table 1).
A single 15 mg/kg dose of amikacin was administered.
Surveillance blood cultures from days 21-26 were negative
for further gram-negative infection. On day 24, a CT scan
of the abdomen with contrast was repeated showing

obstruction despite ongoing diarrhea, thickened and
inflamed segments of jejunum, and persisting duodenitis.
On day 25, the patient was started on bowel rest, and
total parenteral nutrition (TPN) was initiated.
Anidulafungin was administered from days 18-29 for
concern of indolent fungal infection. The patient became
delirious for the remainder of his hospital course. He
received treatment with granulocyte colony stimulating
factor to help bolster his leukocyte counts. The patient
did not defervesce until day 35, at which point his mental
status also improved. On day 37, his ANC surpassed 0.5 x
109/L. On day 38, meropenem was stopped; TPN was
also discontinued as the patient began tolerating an oral
diet. He had no further positive blood cultures. On day
40, a repeat chest x-ray demonstrated improvement of
his right lower lobe and he was deemed medically stable
for discharge to a rehabilitation facility.

DISCUSSION
A case series and literature review of R. ornithinolytica
infections from four university hospitals in France found
bacteremia to occur only in 5% of cases.2 In the setting of
malignancies, there is a 16-patient case series in which 15
had recent underlying malignancies both solid and
hematologic,3 a three-patient case series of bacteremia
with underlying gastric and biliary malignancies,4 and a
report of a patient with acute lymphocytic leukemia (ALL)
who died of R. ornithinolytica sepsis.5 The literature thus
indicates that R. ornithinolytica bacteremia tends to
occur in patients with active comorbidities, especially
malignancies, as in our patient.
Among more resistant R. ornithinolytica isolates, a
blood culture isolate in New Jersey was susceptible
only to amikacin and gentamicin, 6 a blood culture
isolate in Brazil was susceptible only to amikacin,
gentamicin, ciprofloxacin, and levofloxacin,5 and other
carbapenemase-producing strains were found in China7
and Turkey.8 R. ornithinolytica has natural susceptibility
to cephalosporins, carbapenems, aminoglycosides;
intermediate susceptibility to some penicillins, not
usually including piperacillin/tazobactam; and resistance
to macrolides.9
R. ornithinolytica is susceptible to piperacillin-tazobactam
a majority of the time.2-4, 7, 10-11 This case highlights the
importance of antibiotic stewardship to prevent the
inducible resistance that likely contributed to the failure of
piperacillin-tazobactam in this case. Febrile neutropenia
presents an especially difficult challenge as these patient
scenarios often necessitate very long courses of very
broad antibiotics in the absence of identified organisms.
Procalcitonin may be of potential value in guiding
antibiotic administration in patients with febrile
neutropenia. Some data indicate that procalcitonin may
be useful in distinguishing infectious from non-infectious

etiologies of neutropenic fever, as well as trending values
to monitor for response to therapy.12-14
This case also emphasizes the importance of rapid
diagnostics. The assay used in this case used multiplex
polymerase chain reaction (PCR) technology to identify
an organism belonging to the family Enterobacteriaceae
that was specifically not a member of the Klebsiella genus
or other genera within Enterobacteriaceae. This particular
pattern should evoke concern for Raoultella, a former
member of the Klebsiella genus which should be
considered as virulent and resistance-prone as
Pseudomonas. By quickly identifying a new organism,
which persisted through piperacillin-tazobactam therapy,
the assay prompted the switch to meropenem and
prevented the patient from succumbing to his bacteremia.
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